Roger Jeffs Sells 8,360 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 8,360 shares of Liquidia stock in a transaction on Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $121,888.80. Following the transaction, the chief executive officer now directly owns 826,985 shares of the company’s stock, valued at approximately $12,057,441.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Roger Jeffs also recently made the following trade(s):

• On Monday, March 18th, Roger Jeffs sold 28,583 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total value of $452,183.06.

Liquidia Stock Up 2.1 %

NASDAQ LQDA opened at $13.86 on Thursday. Liquidia Co. has a 12 month low of $5.71 and a 12 month high of $16.99. The company has a 50-day moving average of $14.75 and a 200-day moving average of $10.95.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). The company had revenue of $4.53 million for the quarter, compared to analyst estimates of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. On average, sell-side analysts forecast that Liquidia Co. will post -1.01 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on LQDA shares. LADENBURG THALM/SH SH lifted their price target on Liquidia from $15.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, December 21st. Bank of America lifted their price target on Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, December 21st. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of Liquidia in a report on Wednesday, April 10th. HC Wainwright upped their target price on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, March 14th. Finally, Wedbush restated an “underperform” rating and issued a $3.00 target price on shares of Liquidia in a report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.00.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently bought and sold shares of LQDA. Fortitude Family Office LLC acquired a new stake in Liquidia during the 4th quarter worth approximately $26,000. UBS Group AG increased its position in Liquidia by 134.0% during the 2nd quarter. UBS Group AG now owns 7,948 shares of the company’s stock worth $35,000 after purchasing an additional 4,552 shares in the last quarter. Legal & General Group Plc acquired a new stake in Liquidia during the 2nd quarter worth approximately $38,000. BNP Paribas Arbitrage SA increased its position in Liquidia by 42.8% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 10,682 shares of the company’s stock worth $47,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Liquidia by 101.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock worth $55,000 after purchasing an additional 3,524 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).